3-(2,2,2-trimethylhydrazine)propionate has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ball, V; Curtis, MK; Hauton, D; Heather, LC; Holzner, L; Savic, D; Timm, KN; Tyler, DJ | 1 |
| Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Skapare, E; Svalbe, B; Vilskersts, R; Zvejniece, L | 1 |
2 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Alloxan Diabetes
| Article | Year |
|---|---|
Hyperpolarized magnetic resonance shows that the anti-ischemic drug meldonium leads to increased flux through pyruvate dehydrogenase in vivo resulting in improved post-ischemic function in the diabetic heart.
Topics: Animals; Diabetes Mellitus, Experimental; Glucose; Magnetic Resonance Spectroscopy; Male; Metabolomics; Methylhydrazines; Myocardial Ischemia; Myocardium; Pyruvate Dehydrogenase Complex; Rats; Rats, Wistar; Streptozocin | 2021 |
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructosamine; Heart; Hyperalgesia; Hypoglycemic Agents; In Vitro Techniques; Lipids; Male; Methylhydrazines; Myocardial Ischemia; Pain Threshold; Rats; Rats, Wistar | 2009 |